Skip to main content
. 2011 Oct 12;31(41):14508–14520. doi: 10.1523/JNEUROSCI.1560-11.2011

Figure 8.

Figure 8.

Combined UPS and autophagy inhibition with CLBL and BafA1 leads to increased levels of α-synuclein independent of the preexisting α-synuclein burden. Immunoblot levels of α-synuclein in homogenates of recovered cortical tissue of nontransgenic and human α-synuclein transgenic mice after simultaneous treatment with UPS inhibitor CLBL and ALP inhibitor BafA1. Non-tg: 0.43 ± 0.03, n = 17 (vehicle), 0.65 ± 0.06, n = 10 (CLBL+BafA1); ANOVA, p < 0.0001; Dunnett's posttest, p < 0.01; (h)αSyn tg: vehicle: 0.42 ± 0.05, n = 15; CLBL+BafA1: 1.04 ± 0.09, n = 4; ANOVA, p = 0.0001; Dunnett's posttest, p < 0.01. **p < 0.01, compared with vehicle-treated littermates. Error bars indicate SEM.